| 000 | 01760 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516093221.0 | ||
| 264 | 0 | _c20120904 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2012.57 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWilke, R A | |
| 245 | 0 | 0 |
_aThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cJul 2012 |
||
| 300 |
_a112-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Practice Guideline; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aDrug Prescriptions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aLiver-Specific Organic Anion Transporter 1 |
| 650 | 0 | 4 |
_aMuscular Diseases _xchemically induced |
| 650 | 0 | 4 |
_aOrganic Anion Transporters _xgenetics |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aPrecision Medicine |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSimvastatin _xadministration & dosage |
| 700 | 1 | _aRamsey, L B | |
| 700 | 1 | _aJohnson, S G | |
| 700 | 1 | _aMaxwell, W D | |
| 700 | 1 | _aMcLeod, H L | |
| 700 | 1 | _aVoora, D | |
| 700 | 1 | _aKrauss, R M | |
| 700 | 1 | _aRoden, D M | |
| 700 | 1 | _aFeng, Q | |
| 700 | 1 | _aCooper-Dehoff, R M | |
| 700 | 1 | _aGong, L | |
| 700 | 1 | _aKlein, T E | |
| 700 | 1 | _aWadelius, M | |
| 700 | 1 | _aNiemi, M | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 92 _gno. 1 _gp. 112-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2012.57 _zAvailable from publisher's website |
| 999 |
_c21802327 _d21802327 |
||